a b s t r a c t F-box proteins (FBP) are the substrate specifying subunit of Skp1-Cul1-FBP (SCF)-type E3 ubiquitin ligases and are responsible for directing the ubiquitination of numerous proteins essential for cellular function. Due to their ability to regulate the expression and activity of oncogenes and tumour suppressor genes, FBPs themselves play important roles in cancer development and progression. In this review, we provide a comprehensive overview of FBPs and their targets in relation to their interaction with the hallmarks of cancer cell biology, including the regulation of proliferation, epigenetics, migration and invasion, metabolism, angiogenesis, cell death and DNA damage responses. Each cancer hallmark is revealed to have multiple FBPs which converge on common signalling hubs or response pathways. We also highlight the complex regulatory interplay between SCF-type ligases and other ubiquitin ligases. We suggest six highly interconnected FBPs affecting multiple cancer hallmarks, which may prove sensible candidates for therapeutic intervention.
Introduction
The post-translational modification (PTM) of a protein by conjugation with a 76aa peptide called ubiquitin was first described as fating that protein for destruction by the proteasome. This reaction is catalysed by ubiquitin ligases and together with the proteasome, they are collectively known as the ubiquitin-proteasome system (UPS). However, protein destruction is only one outcome, as there is considerable variety in ubiquitin modifications, ranging from which amino acids undergo PTM, to the number of ubiquitin monomers added, to the types of linkages fashioned. This complexity is deemed the 'ubiquitin code', which conveys signals for outcomes including changes in subcellular localisation, activity, and signalling [1] . Ubiquitination therefore plays an integral role in every aspect of cell function, and discovering and understanding its activity is central to biology.
Ubiquitination, as an enzymatic cascade, is well-reviewed [2, 3] . The largest family of E3 ubiquitin ligases is the cullin-RING ligase, which includes SCF-type ligases, consisting of Skp1/Cul1/Rbx1 and an F-box protein (FBP), defined by its F-box motif. The cullin backbone (Cul1) provides a rigid scaffold, and also binds to the RING-domain containing protein, Rbx1, which recruits an E2 enzyme bearing a charged ubiquitin. Cul1 also binds to Skp1, which promoting angiogenesis. Considered foremost a genetic and/or epigenetic disease, cancer has been vigorously probed as to the nature of the causative genetic changes and whether they classify as 'oncogenes' (OG) or 'tumour-suppressor genes' (TSG). Cancers are also heavily influenced by their tumour-associated stroma and the immune responses they invoke, and these cell-extrinsic influencers are also viewed in this way. This simple, practical and thus widely used classification can underplay the complexity of networks in which signalling pathways operate. The result is some gene functions are classified as operating as OG and TSG or in some cases as both, depending on the specific context or cell type. We refer the reader to an excellent review on the classification of FBPs on their OG or TSG potential [11] .
In this review, we map the reported substrate interactions of FBPs into functional categories comprising the hallmarks of cancer, and in so doing, reveal some of the pathways controlled by multiple FBPs (Fig. 1) . Four FBPs have the vast majority of substrates: Fbxw7 has 36, Skp2 (Fbxl1) has 40, and ␤-Trcp1/2 (Fbxw1/Fbxw11) have over 75; these FBPs are extensively reviewed elsewhere [8, [12] [13] [14] [15] [16] [17] [18] [19] [20] . As might be expected, these four FBPs impact on all cancer hallmarks ( Fig. 2A-C ). However, due to space considerations, they are mentioned herein where they overlap with substrates and pathways of less cited FBPs. We note this 69-member family now has only eight members with no primary literature (Fbxl8, Fbxl13, Fbxw9, Fbxw10, Fbxw10B, Fbxo16, Fbxo34, and Fbxo46).
Sustained proliferation by promoting cell cycle progression
Promoting the G1 to S transition is controlled by several FBPs that do so canonically, i.e. by promoting UPS-mediated degradation of substrates, as exemplified by SCF(Skp2) targeting CDKIs p21, p27, and p57 for degradation (reviewed in [13, 21] ). During G1, Dtype cyclins rely on p21 and p27 to assemble with their cognate Cdks, paradoxically making these 'inhibitors' important for facilitating progression through early G1 [22] . p27 is considered a sensor of phosphorylation events that promote cell cycle entry, and phosphorylation of p27 dictates its localisation, activity, and stability. Although a number of ubiquitin ligases trigger CDKI degradation (reviewed in [23] ), a another FBP, Fbxl12, indirectly affects p27 by regulating one of its kinases [24] . Ca 2+ /CaM-dependent kinase 1 (CaMK1), which responds to intracellular calcium levels, an important determinant for cell cycle entry, phosphorylates p27 on T157 and T198, directing it to the cytoplasm and preventing its activity as an inhibitor. Increased SCF(Fbxl12) promotes CaMK1 degradation, causing G1 arrest due to aberrant phosphorylation and localisation of p27, and lack of assembly of cyclin D1/Cdk4 complexes [24] .
Cyclin D/Cdk activity is a focal point for ubiquitination, and a number of FBPs are reported to direct ubiquitination toward D-type cyclins, subsequently promoting their proteasomal degradation. For cyclin D1, these include SCF(Fbxw8) [25] , SCF(Fbxo4) [26] , SCF(Fbxo31) [27] , SCF(Skp2) [28] , and SCF(␤-TRCP) [29] ; SCF(Fbxl2) acts similarly towards cyclins D2 and D3 [30, 31] . Notably, SCF(Fbxo31) is thought to initiate cyclin D1 degradation in response to DNA damage (Fig. 2D) . The stress-activated kinase ATM phosphorylates Fbxo31 on S278, stabilising Fbxo31 expression, thereby promoting the ubiquitination and degradation of cyclin D1, activating the cell cycle arrest checkpoint. Interestingly, the phosphorylation of cyclin D1 by ERK signalling creates a phosphodegron for recognition by SCF(Fbxo31) [27] . In contrast to the pro-degradative activities of these multiple FBPs, Fbxo7 interacts with but stabilizes p27 and also promotes the association of D-type cyclins with Cdk6 affecting proliferation and invasiveness (Fig. 2E ) [32] [33] [34] . This non-canonical activity is independent of ubiquitination, but appears to rely on a bi-partite interaction that 'scaffolds' the association of interacting proteins. The critical role of D-type cyclins in regulating entry into S phase is well attested to, as it is regularly mutated in cancer [35] . The fact that several FBPs have been suggested to regulate their activity/abundance is also perhaps not surprising given the highly interconnected nature of their signalling networks both leading into and acting downstream of them. That multiple FBPs can regulate cyclin D levels suggests they can independently sense and relay these signals onto the cyclin D hub, thus imparting redundancy and robustness to this important regulatory network. Downstream of the D-type cyclins/Cdk/pRb pathway, G1/S phase cyclins are also regulated by FBPs: SCF(Skp2) ubiquitinates cyclins E and A, and SCF(Fbxw7) ubiquitinates cyclin E. In these cases, proteasome-mediated degradation ensues (reviewed in [5] ). The restriction point for entry into the cell cycle is clearly a major focal point for FBP regulation.
In addition to their key participation at cell cycle entry, FBPs also play integral roles in G2 and M phases. For example, SCF(Fbxo31) also acts to ensure S phase completion and single-usage of origins of replication, by ubiquitinating the replication licensing factor Cdt1, facilitating its degradation [36] . Cdt1 has also been proposed as a substrate for SCF(Skp2) [37] . Normal regulation of the cell cycle might be perturbed if Fbxo31 were mutated, potentially promoting genomic instability. Also acting on this critical aspect of replication fidelity is Fbxo5/Emi1, which was first described as inhibiting the mitotic E3 ligase, APC/C, but not while part of an SCF ligase. Emi1's primary role is linking DNA replication with mitosis. When Emi1 levels are reduced, DNA re-replication occurs due to the degradation, by APC/C(Cdh1), of the replication licensing inhibitor, geminin, which inhibits Cdt1 [38, 39] . DNA re-replication can lead to activation of DNA damage checkpoints (see Section 7). A second FBP, Fbxo43 (also called Emi2), acts in a similar manner to Emi1 to block exit from anaphase in Xenopus egg extracts [40] . Interestingly, Emi1 is a substrate for SCF(␤-TRCP), and this is thought to be an important checkpoint controlling APC/C activation in late G2 [41] . In fact, SCF(␤-TRCP) ubiquitinates multiple mitotic regulators, including Cdh1, Cdc25A/B, Plk4, Wee1A, Bora, and Mis18␣. It also acts as a regulator of the spindle checkpoint during mitosis, by controlling the ubiquitination and degradation of securin under UV-stress conditions [42] .
Other substrates for ubiquitination during mitosis include the Aurora kinases, which coordinate chromosomal partitioning and cytoskeletal events [43] . Aurora kinases are also regulated by SCF(Fbxw7) and by the APC/C [43] . Additionally, Aurora kinase B (AurKB) has multiple E3 ligases that promote its ubiquitination and degradation, including Cul3/Klhl21 [44] and Klhl3/9/13 [45] , and BRAD1 [46] . However, two studies point to additional regulation by FBPs: SCF(Fbxl2) ubiquitinates and destabilizes AurKB [47, 48] and SCF(Fbxl7) targets Aurora kinase A (AurKA) [49] . Given the vital role of the Aurora kinases in mitosis, the pursuit of an inhibitor is intense, and several are moving through clinical trials [50, 51] . Interestingly, a small molecule stabilizer of Fbxl2 levels enhanced the degradation of AurKB, resulting in mitotic arrest and apoptosis [48] . Thus it is possible to target FBP regulators of key oncoproteins, which might be a more tolerable therapeutic route than directly targeting the oncoprotein itself.
Another important player in cell division is the centrosome, which serves as a microtubule organizing centre (MTOC) for the mitotic spindle (reviewed in [52] ). The centrosome duplicates during S phase and matures over the course of the cell cycle, and is tightly controlled by the core S phase kinases, cyclins E/A/Cdk2, including the direct phosphorylation of three centriolar proteins, NPM, CP110, and MPS1. If centrosome duplication, maturation or segregation is mis-regulated, this can contribute to tumour progression through the formation of multipolar spindles. The centriolar protein, Sas6 is a core protein essential for centriole duplication. Sas6 is targeted for ubiquitin-mediated degradation by SCF(Fbxw5) [53] . During G2/M phase, Fbxw5 is itself ubiquitinated and degraded by APC/C in response to phosphorylation by PLK4. This cell cycle restricted abundance of Fbxw5 ensures the fidelity of the centrosome cycle. The other FBP which impacts on centrosomes is SCF(Fbxo1) (cyclin F) which is also cell cycle regulated. Fbxo1 is required to degrade CP110, in a timely fashion. This is evidenced by the fact that Fbxo1 depletion during G2, or a hyperstable CP110, caused defects consistent with genomic instability [54] . Another SCF(Fbxo1) substrate that regulates chromosomes is NAUSP1, which is a microtubule regulator participating in chromosome condensation and congression during mitosis [55] . NAUSP1 is degraded during S and G2 phases, but can also be degraded in response to UV-mediated DNA damage, although this is not catalysed by SCF(Fbxo1), indicating another protein regulates its response to DNA damage. Fbxo1 also regulates the checkpoint at G2 in response to ionising radiation in a non-canonical manner, possibly by competing with cyclin A/Cdk for binding to transcription factor (TF) B-Myb [56] . This prevents the cyclin A/Cdk phosphorylation of B-Myb, thereby crippling its transactivation of genes like PLK1, cyclin B and cyclin A, and AurKA, which promote entry into mitosis. Other FBPs also interface with Myb TFs. It has been shown SCF(Fbxw7) ubiquitinates c-Myb promoting its degradation in a canonical fashion, but Fbxw5, via a DDB1/Cul4A/Rbx1 complex, promotes the sumoylation of c-Myb, which suppressed its activity as a TF [57] . Thus, multiple FBPs converge on c-Myb, potentially modulating mitosis. Quite apart from the oscillating cell cycle, FBPs also regulates the oscillating circadian clock. Cryptochrome (CRY) proteins, together with period (PER) genes, comprise the regulatory system for the circadian clock. SCF(Fbxl3) promotes ubiquitin-mediated degradation of CRY proteins, and SCF(Fbxl21) protects CRY proteins from Fbxl3 ubiquitination by antagonizing Fbxl3's ligase activity [58] . Interestingly, SCF(␤-TRCP) also ubiquitinates PER proteins [59] . The functional relevance of disruption to the circadian clock to cancers is proposed to be via their effects on gene expression of regulators of metabolism and cell cycle genes, like c-Myc, Wee1, and cyclin D1 [60] .
Sustaining proliferation by blocking differentiation
During cell specification, the commitment of a stem cell to a particular lineage and the establishment of a cell type-specific expression pattern usually occurs over a few cell divisions. This process culminates in terminal differentiation, which includes cell cycle exit, resulting in a specialized cell type [61, 62] . Whereas some cancer types, such as chronic myeloid leukaemia, show extensive proliferative defects but little effect on differentiation, most cancers are compromised in some way in both processes. This is because cell cycle arrest and differentiation are tightly linked, and it is interesting to note that prevention of one can lead to defects in the other. For example, during erythropoiesis in mice lacking Fbxo7 or overexpressing cyclin E, erythroblasts undergo more cell divisions yet fewer mature cells are produced, causing anaemia and other dysplastic phenotypes [63, 64] . Fbxo7, by virtue of its stabilisation of p27, can also slow B cell proliferation, and B cells lacking Fbxo7 have a faster cell cycle and show a concomitant reversal in differentiation markers, suggesting a linked mechanism whereby slowing the cell cycle aids differentiation [34] . Withdrawal in G1 is enforced by cell cycle inhibitors, like CDKIs, and retinoblastoma family proteins (pRB, p110, and p130). SCF(Skp2) targets all CDKIs (mentioned above) and also promotes the degradation of p130, which enforces cell cycle withdrawal and the commitment to differentiation through its negative regulation of E2F proteins [65, 66] .
FBPs also directly target proteins involved in differentiation, including those that induce or inhibit differentiation programs. SCF(Fbxo21) ubiquitinates and degrades a protein called E1A-like inhibitor of differentiation 1 (EID1) [67] , which binds to TFs and co-activators, including pRb, p300 and CBP. Together, this prevents MyoD transactivation, which is a master regulator of muscle specification [68] . It has been proposed that EID1 needs to be degraded to stimulate differentiation, and that inhibition of p300 HAT activity, in particular, is mechanistically important. EID1 has also been shown to interact with a pluripotency factor Pcid2, and thus affect the ability of stem cells to self-renew [69] . It is possible that, in cancers originating in stem cells, the levels of EID1 may be important in maintaining tumour initiating cells.
Another pluripotency factor targeted by FBPs is Krüppel-like factor 4 (KLF4). KLF4 is a TF involved in basic cell functions, particularly in epithelial and endothelial cells (reviewed in [70] ), and thus, its deregulation has pathological effects in many tissues, including the intestine, skin, and vascular endothelium. Over-expression of KLF4, along with Oct4, c-Myc, and Sox2, can re-establish a pluripotent state in cells. In this context, KLF4 is thought to counteract the pro-apoptotic effect of c-Myc over-expression, thus enabling proliferation to prevail. Because of these pro-survival properties, KLF4 has been proposed to be an OG, but in certain contexts can also have TSG functions. In hepatocellular carcinoma (HCC) cells, SCF(Fbxo22) can ubiquitinate KLF4 causing its degradation, promoting cell proliferation, anchorage independence, and invasiveness. These phenotypes and the increased Fbxo22 levels found in patient samples suggest a TSG role for KLF4 in this cell type [71] .
There are three FBPs, Fbxo30, Fbxo32 and Fbxo40, which are expressed primarily in myocytes, which suggests any role (s) in tumour formation would be limited to those cells. Although to date they have no documented roles in tumourigenesis, they ubiquitinate substrates known to play a role in oncogenesis. For example, SCF(Fbxo32), also called MAFbx/Atrognin-1, has been shown to promote degradation of c-Myc [72] , while SCF(Fbxo40) promotes degradation of insulin receptor substrate 1 (IRS-1), which mediates insulin signalling to the PI3K/Akt pathway [73] . Interestingly, IRS-1 is also targeted by SCF(Fbxw8), so at least two FBPs converge at this signalling hub. SCF(Fbxo30) functions downstream of BMP (bone morphogenic protein) signalling (see Section 4) [74] .
In thinking how such factors may play a role in tumourigenesis, one could imagine scenarios in which the prevention of myocyte differentiation, or inappropriate growth factor signalling in a mesenchymal precursor cell, could instigate transformation to a sarcoma.
Sustaining proliferation through increased receptor signalling
Cells respond to their environment through contact with the surrounding stroma, and via receptor signalling in response to growth factors and cytokines. Receptor signalling pathways translate these external signals into internal responses such as changes to gene expression, and they provide an efficient way to promote or control cell proliferation, cell death and cellular change in response to the external environment [75] [76] [77] . Mitogenic and pro-survival receptor signalling pathways are often deregulated in cancer, including but not limited to growth factor receptor pathways controlled by EGFR, FGFR, and ERBB2, as well as WNT, Notch, and Sonic Hedgehog cytokine signalling pathways. Cross-talk among receptor signalling pathways display a robustness and redundancy which is problematic for cancer therapeutics [78] [79] [80] [81] [82] [83] . This is evidenced by the fact that pharmacological inhibitors to specific receptors are often bypassed by increasing signalling via a different receptor. However, often these different receptors converge on common hub proteins downstream, providing opportunities for broader therapeutic intervention. Downstream mediators of receptor signalling include the PI3K/AKT and Ras/MAPK pathways, both of which are repeatedly mutated in cancer, and many of which are regulated by FBPs.
Some FBPs can also interact with more than one signalling pathway. The FBPs with the most substrates, Skp2, Fbxw7 and ␤-TRCP have many targets in signalling pathways, e.g., SCF(Skp2) ubiquitinates Akt1, DUSP1, JAK3, and RASSF1A; SCF(Fbxw7) ubiquitinates mTOR, B-Raf, NF1, and Presenilin; and SCF(␤-TRCP) ubiquitinates PHLPP1 and H-Ras. Fbxw8, via Cullin7 binding, interacts with multiple receptor signalling pathways promoting their ubiquitinmediated degradation. This includes its regulation of (i) TBC1D3, a putative oncoprotein that facilitates growth factor signalling, including via Ras [84] , (ii) HPK1, which is a MAP4K that impacts on a multitude of signalling pathways, including ERK, JNK, TGF-␤, NF-B pathways, and blood cell signalling receptors, like erythropoietin, TCR, and BCR [85] , (iii) IGFBP2, which regulates cellular growth control [86] , and of (iv) IRS-1, which transduces insulin signalling to both MAPK and PI3K signalling pathways [87] . SCF(Fbxl2) has also been shown to control the PI3K signalling pathway via the ubiquitination and degradation of the PI3K regulatory subunit, p85␤, when not bound to a catalytic p110 subunit [88] . Interestingly, the interaction of Fbxl2 with p85␤ is prevented by its phosphorylation on Y655, and the tyrosine phosphatase, PTPL1, that removes this modification also interacts with SCF(Fbxl2). This regulatory interaction functions in relaying growth factor signalling via receptor tyrosine kinases, like PDGFR, or insulin through IRS1. For example, decreases in Fbxl2, allowed accumulation of p85␤, which competed with catalytically active p85-p110 heterodimeric kinase for binding to IRS1. The net effect was attenuation of PI3K signalling, and downstream of that an increase in autophagy [88] .
mTOR, a component of both mTORC1 and mTORC2 complexes, and a mediator of receptor signalling and sensor of nutrients, amino acids, and stress, is related to the PI3K family and regulates many cellular functions. mTORC1 affects functions like cell growth, proliferation, survival, protein synthesis, and autophagy, while mTORC2 regulates Akt signalling and the cytoskeleton. DEPTOR, an inhibitor of mTORC1 pathways, but activator of mTORC2, has also been shown to be ubiquitinated by SCF(␤-TRCP) [89] [90] [91] . mTORC1/2 have as integral components, the Tel2 and Tti1 proteins, which are phosphorylated by mTORC1 when growth factors become limiting. This retards both protein translation and subsequent cell growth. In addition to mTOR, Tel2/Tti1 proteins control the assembly of the PI3K kinase (PIKK) family, which include DNA damage responsive kinases ATM, ATR, DNA-PKcs, and TRRAP. SCF(Fbxo9) has been shown to ubiquitinate Tel2 and Tti1 proteins, resulting in their degradation, and thus could potentially impact on all of the activities of PIKKs [92] . Its effects on mTOR have been directly investigated, and in this context, Fbxo9 appears to direct cells towards cell survival when growth factors become limiting, constitutively stimulating the mTORC2 pathway. These studies suggest that Fbxo9 might act as an OG, which is supported by its being overexpressed in myeloma patients [92] . Other regulators of mTOR signalling include Cul4(Fbxw5) E3 ligase, which was shown to promote ubiquitination and degradation of TSC2, a negative regulator of mTOR signalling [93] .
Downstream of TGF-␤ and BMP signalling pathways are the Smad ubiquitination-regulatory factors (Smurfs), which are themselves E3 ubiquitin ligases (reviewed in [94] ). The main family members are Smurf1 and Smurf2, and they were originally cloned as Smad1 interacting proteins, and thus characterized initially as being important mediators of TGF-␤/BMP signalling. However, due to their greatly expanding repertoire of substrates, their influence over a multitude of pathways is becoming more apparent. The regulatory network downstream of Smurf1 is extensive, and includes negative regulation of many SMADS, TRAF4, KLF2, RUNX2/3, and RhoA, which can affect proliferation, apoptosis, differentiation, and cell migration. The network for Smurf2 is even broader, and includes RNF20 and Id1/3 proteins that impact on genome stability and senescence. Smurfs are aberrantly expressed in cancers, with Smurf2 characterized as a TSG. However, given this wide, pleiotropic network of influence, it is perhaps not surprising that Smurfs are deemed to act on both pro-and anti-tumour formation in a context-dependent manner. SCF(Fbxl15) was the first FBP shown to ubiquitinate Smurf1/2, and promote their degradation by the proteasome [95] . The functional relevance of this was demonstrated in its restrictive effects on BMP signalling, via ubiquitination of phosphorylated Smad1/5, which was important for dorsoventral patterning in zebrafish embryos. SCF(Fbxo3) has also been shown to promote the ubiquitin-mediated degradation of Smurf1/2 and also all the other Nedd4 family members (Nedd4-1, Nedd4-2, NEDL-1, NEDL-2, WWP-1, WWP-2 and ITCH) [96] . The decrease in Smurf1 levels promoted the stabilization of its substrates, including Smad1/5, the consequential effect being an increase in BMP signalling. Although these studies looked at BMP signalling, it is not unreasonable to expect Fbxl15 and Fbxo3 to negatively regulate the Smurf networks as they operate in particular cell types. Interestingly, the signal transducer Smad4 is also targeted by SCF(Skp2) and SCF(␤-TRCP), suggesting that multiple FBPs are engaged with the regulation of the TGB-␤/BMP signalling pathways [97, 98] .
Signalling in response to environmental and genotoxic stresses and inflammatory cytokines is channelled through the intracellular SAPK/JNK, and p38 MAPK pathways. These pathways can crosstalk and play essential roles in mediating the cell's inflammatory and acute stress responses. p38 family members are activated by kinases known as MAP2Ks, and one of these kinases, MKK6 has been shown to be a substrate for SCF(Fbxo31) [99] . MKK6 is destabilized as a result of ubiquitination by Fbxo31. Sustained activation of the p38 stress response pathway can eventually precipitate cell death, but this can be mitigated by the over-expression of Fbxo31. In a cancer setting, interfering with the activity of SCF(Fbxo31) might affect the tumour's ability to respond to stress or to chemotherapy.
The cellular response to activated signalling pathways from cell surface receptors usually involves rapid transcription of response genes. Examples of TFs downstream of these include c-Myc, bMyb, and E2F, as well as ER␣, Jun, and FOXO. Many of these oncogenic TFs have also been documented as being targets of SCF(Skp2), SCF(Fbxw7) or SCF(␤-TRCP1/2) ligases (reviewed in [11] ). Other examples, include Elk1, which was originally identified as a TF downstream of ERK signalling, which subsequently up-regulates, for example, the proto-OG c-Fos [100] . Other targets in the Elk1 transcriptional network include the core gene regulation machinery, basal transcription machinery, spliceosome subunits, and ribosomal proteins [101] . SCF(Fbxo25) has been shown to ubiquitinate Elk1 promoting its degradation by the proteasome, and increased expression of Fbxo25 was capable of suppressing the expression of Elk1 target genes [102] . Thus loss of Fbxo25 might enhance Elk1 levels and bypass mitogenic signals upstream of Elk1. Another example of FBPs affecting transcriptional responses is the SCF(Fbxo3) ligase, which was found to be regulated by promyelocytic leukaemia protein (PML) [103] . As part of the PML complex, PML delayed the degradation, by SCF(Fbxo3), of two other transcriptional co-activators, HIPK2 and p300, until transcription of target genes was complete. PML is proposed to act as a TSG, so this highlights its mechanistic role as preventing degradation of cofactors. In the case of PML/HIPK2/p300, their combined activities enhanced p53 transactivation, and so can affect the DNA damage response.
Epigenetic dysregulation
Deregulation of the epi-genome is another accepted mechanism that results in extensive changes to gene expression in cancers [104, 105] . FBPs can directly and indirectly affect the epi-genome. Fbxl10 (KDM2B/JHDM1B) and Fbxl11 (KDM2A/JHDM1A) function as ubiquitin ligases but also as demethylases, which can modify histone H3 [105] [106] [107] . Several lysines within histone H3 can be modified, and these are important for both transcriptional activation and repression and also play roles in the DNA damage response. In histone H3, K4, K9, K27, K36, and K79 can be modified and this can be by mono-, di-, or tri-methylation. Interestingly, Fbxl11 was the first JmjC domain-containing histone demethylase to be identified, and it specifically removes mono-and di-methylation from K36 [108] . Both of these genes were identified in an insertional mutagenesis screen using retroviruses for TSGs [109] . Coupled with the fact that altered heterochromatin is thought to be an important factor in cancer [110] , it is likely that these dual function FBP/demethylases are targeting critical loci or TFs in tumour development. Candidates for this include Fbxl10 repression of TFs including the AP-1 subunit c-Jun [111] , and NF-B subunit p65 [112] . Whether the ubiquitination function of Fbxl10 and Fbxl11 impinges on their demethylase activity is not yet known, but they are the only demethylases in the 31 member protein family that contain F box domains [106] . Many FBPs can associate with chromatin suggesting ubiquitination is an important means to control chromatin biology and dynamics.
FBPs can also indirectly affect the balance of histone modifications that can promote tumour formation, SCF(Fbxl4) and SCF(Fbxo22) both converge on a histone lysine demethylase, KDM4A/JMJD2A, which removes di-and tri-methylation from K9 and K36 of histone H3 [113, 114] . Interestingly, KDM4A interacts with pRB and is important for its inhibition of E2F proteins [115] . It is possible that these two FBPs are targeting the tumour suppressor activity of pRb by destabilizing its co-factor. KDM4A is also thought to be functionally important in S phase progression to coordinate chromatin modification with DNA replication, thus safeguarding genome stability. For example, loss of the Caenorhabditis elegans homolog causes increased cell death [116] . Thus, one might expect over-expression of Fbxl4 or Fbxo22 to be detrimental to cells. Separate to this study, however, Fbxl4 has been associated with rare cases of an early onset mitochondrial encephalomyopathy. These patients show defects in mitochondrial maintenance due to a loss of mitochondrial DNA, but molecular mechanisms are unknown [117, 118] . In these studies, Fbxl4 is clearly localised to the inter-membrane space of mitochondria, suggesting its functional relevance is limited to this organelle. Since mitochondria lack histones, this suggests Fbxl4 must have other targets therein.
Resisting cell death
That cancer cells refuse to die is perhaps the hallmark that most defines this disease, and one which contributes to the ineffectiveness of some chemotherapeutic agents. The transcriptional response to cellular stresses, including DNA damage, hypoxia, and OG-activation, are most famously coordinated and calibrated by the pro-apoptotic TF p53 [119] [120] [121] . It was thought that the primary function of p53 was to 'handle' the normal double stranded breaks (DSB) that occur during crossover events during meiosis. Its roles have since expanded and it is important for safeguarding genome integrity. The main regulator of p53 is an E3 ubiquitin ligase, Mdm2, a HECT domain family member; however, it has been recently shown that Fbxo31 plays an important and direct role in the p53 response. After DNA damage, p53 levels are elevated to mobilize the cell's response, either cell cycle arrest and repair, or apoptosis. A key factor to increase p53 levels, which are normally kept low by the degradative action of Mdm2, is the down-regulation of that ligase. Mdm2 levels can be destabilized by the SCF(Fbxo31) ligase [122] . To allow this, ATM phosphorylates both Fbxo31 and Mdm2, facilitating the recognition of Mdm2 by SCF(Fbxo31). This makes Fbxo31 a potential TSG, and indeed, it appears to be mutated in solid tumours. Mdm2 is also ubiquitinated by SCF(␤-TRCP) which recognizes a phospho-degron created by casein kinase I (CKI) after DNA damage [123] . Thus kinases and FBPs redundantly hone in on Mdm2 during the damage response. An alternative means of inactivating p53 is catalysed by SCF(Fbxo11) which can act in a noncanonical fashion to neddylate p53 on two lysine residues (K320, K321) within its nuclear localisation signal, distinct from sites in the C-terminal regulatory region neddylated by Mdm2. The modifications by Fbxo11 suppress p53 transcriptional activity but do not affect its abundance (Fig. 2F) . The other p53-related factors are also targeted by FBPs, including p63 which is ubiquitinated and degraded by SCF(Fbxw7) [124] , but ubiquitinated and activated by SCF(␤-TRCP) [125] . In addition, SCF(Fbxo45) specifically ubiquitinates p73 promoting its degradation [126] . This study also reported that a HECT E3 ligase can also destabilize p73 under genotoxic conditions, which indicates that multiple ubiquitin ligases act on the same proteins. Importantly, they report that depletion of Fbxo45 can sensitize cells to die in response to DNA damaging agents even in a p53 null setting. Given the frequency with which the p53 pathway is targeted in cancer, agents that inactivate Fbxo45 might provide an alternate means to engage the cell's apoptotic pathways [126] .
Another TF family with TSG properties is the class O forkhead box (FOXO) proteins, FOXO1, 3, 4, and 6. Like the p53 family, they affect numerous cellular pathways, including cell metabolism, cell cycle, resistance to oxidative stress, and apoptosis, but seem to act primarily to regulate tissue homeostasis in response to cell stresses [127] . FOXO TFs are, however, also responsive to signalling pathways, including insulin and growth factor receptors that signal through PI3K/AKT, and which inhibit their activation. FOXO TFs are heavily modified by PTMs, receiving multiple extrinsic signals and coordinating an integrated response. FOXOs can be ubiquitinated by FBPs: Foxo1 and Foxo3a are destabilized by ubiquitination by SCF(Skp2), and Foxo3a, by SCF(␤-TRCP), and interestingly, FOXOs are also regulated by Mdm2. These SCF ligases could thus be considered to have OG capacity via the destabilization of a FOXO transcriptional response.
In addition to a transcriptional response, there is a vast protein network that executes the cell death response. The pathways that bring about cell death, both intrinsic (mitochondrial) and extrinsic (death receptor), are frequently targeted in cancer. Both pathways ultimately activate intracellular caspases. The intrinsic cell death pathway is regulated by the anti-apoptotic Bcl-2 family of proteins, Bcl-2, Mcl-1, Bcl-w and Bcl-x L , that normally act at the mitochondrial membrane surface to prevent the embedded Bax and Bak pro-apoptotic proteins from promoting mitochondrial outer membrane permeabilization, and the release of apoptotic proteins, including cytochrome C and inhibitor of apoptosis (IAPs) proteins. However, under irreparable damage or stress conditions, a suite of pro-apoptotic BH3-only family members (Bid, Bad, Bim, Puma, Noxa, Beclin-1) bind to and inhibit anti-apoptotic proteins allowing apoptosis to proceed. Interestingly, these BH3-only proteins also co-regulate autophagy pathways, which are involved in tumour development [128] .
Several lines of evidence exist for the involvement of FBPs in controlling cell death by catalysing the ubiquitination of Bcl-2 family proteins, include ubiquitination of Mcl-1 by SCF(Fbxw7) and SCF(␤ -TRCP) [129, 130] , and of BimEL by SCF(␤-TRCP) [131] . A more direct intervention by a ubiquitin ligase variant directed by ␤-TRCP was reported to promote pro-caspase 3 degradation, raising the threshold for apoptosis induction [132] . The Hax-1 family of proteins also contain Bcl-2 homology domains which involve it in the intrinsic cell death pathways, and they have been shown to have pro-survival effects, and be up-regulated in cancers [133] . They interface with a large array of proteins, attesting to a complex biological role. Hax-1 has recently been shown to be a substrate for ubiquitin-mediated degradation by SCF(Fbxo25) [134] . Interestingly, Hax-1 and Fbxo25 normally reside in distinct subcellular compartments, Hax-1 at the mitochondria, and Fbxo25 in the nucleus, but upon stimulation with etoposide, protein kinase C ␦ phosphorylates both proteins triggering Fbxo25 translocation to the mitochondria and the appearance of a phospho-degron on Hax-1 enabling SCF(Fbxo25) binding. Reduced Fbxo25 expression was found to negatively correlate with survival in an E-myc mouse model of lymphomagenesis. Thus, Fbxo25 can be considered to have TSG activity by suppressing Hax-1 pro-survival activity. Indeed it has been found to be a haplo-insufficient TSG in an aggressive blastoid variant of mantle cell lymphoma [134] .
Evidence for the role of Fbxo10 in cell death comes from developmental studies in C. elegans. Its Dre-1 protein is thought to be related to human Fbxo10 and Fbxo11 by virtue of the presence of a carbohydrate-binding and sugar hydrolases (CASH) domain. Dre-1 is important for the development of larval tissues, imparting both positional and temporal identities, thus dictating cell fates [135] . Dre-1 interacts with the anti-apoptotic protein Ced-9, a homolog of Bcl-2, and promotes its degradation. In human cells, levels of Fbxo10 inversely correlate with Bcl-2, and Fbxo10 over-expression in cells induces apoptosis, which can in part be rescued by increased Bcl-2 expression. Support for the possibility that Fbxo10 might act as a TSG comes from studies of DLBCL which have decreased expression of Fbxo10 [136] . Interestingly the other CASH domaincontaining FBP, SCF(Fbxo11), has been shown to degrade Bcl-6, a TF that regulates a swathe of genes involved in differentiation, maturation and activation of B cells [137] . The negative regulation of Bcl-6, an OG over-expressed in B cell malignancies, including aggressive DLBCLs, by Fbxo11, makes it a putative TSG, which interestingly, has been shown to occur in up to 14% of DLBCL cases, and may require the inactivation of only one allele [137] . Mutations in FBXO11 have also been found in other cancer types [138] [139] [140] . Fbxo11 has the additional enzymatic activity of being able to methylate arginines and is also known as PRMT9 [141] . Although protein methyltransferases have multiple roles with relevance to cancer, this enzyme has not yet been characterized [142] .
An example FBP interaction with an extrinsic death receptor pathway is Fbxl2. SCF(Fbxl2) degrades TRAF proteins which acts downstream of TNFR signalling, which is important in a number of diverse signalling pathways, ranging from cell death to inflammation. The TRAF family of proteins are responsible for mediating signals from this receptor, as well as other cytokine receptors. Fbxl2 has been shown to degrade TRAF family members, and in turn, SCF(Fbxo3) mediates the ubiquitination and degradation of Fbxl2. A subset of TRAFs (2, 5 and 6) signal to the NFB pathway that is important in cytokine signalling and cell survival. TRAF1 and 2, as well as cIAP1, are ubiquitinated by SCF(Fbxo7), inhibiting their function but not affecting their expression [143] . As such, Fbxo7 is a negative regulator of NFB signalling. Other FBPs that converge onto this signalling pathway, include most notably SCF(␤-TRCP), which recognizes phospho-degrons created by IKK on multiple NFB pathway factors including IB␣, IB␤, and IB, the p105 and p100 TFs, the IRAK1 protein kinase, two adaptor proteins Bcl10 and CIKS, and also p53 [13, 144] .
DNA damage and genome integrity
Homologous recombination (HR) is an important process that enables the repair of damaged genes, collapsed replication forks, and the maintenance of chromosomes [145] [146] [147] . The process is multi-step, beginning with the sensing of DNA damage by ATM/ATR kinases, their phosphorylation of signalling transducers, like Chk1, p53, BRCA1, and H2AX, which mobilize cellular responses to damage, and the repair of broken ends, involving end re-sectioning by the MRN (Mre11, Rad50, NBs1) complex, the binding of a Rad51 nucleofilament on exposed single strand (ss) DNA ends, and subsequent strand invasion and repair [148] . HR is an error-free method of repair, and as such, the function of the players and the fidelity of the process are important for maintaining genetic integrity. As outlined, HR is dependent on a host of other proteins and HR deficiency in cancer is well documented. Many HR genes, when mutated, are recognized to contribute to cancer susceptibility [149] . FBPs act directly at several points in this HR cascade.
One of the key initiating steps in the damage response is the phosphorylation of human ssDNA binding protein 1 (hSSB1) by ATM. hSSB1 has a short half-life, being normally ubiquitinated by SCF(Fbxl5), which results in its degradation [150] . hSSB1 phosphorylation by ATM prevents its recognition by Fbxl5, thus sparing it from the proteasome, and stabilising its levels. hSSB1 acts as part of a hetero-trimeric complex called Sensor of ssDNA complex 1 (SOSS1), and it is an important factor in cellular ATM response to genotoxic stress. In addition to this, hSSB1 aids in the recruitment and activity of the MRN complex, and regulates the stability of p53 in cells [151] .
Chk1 is a direct phosphorylation target of the ATM/ATR kinases enforcing the DNA damage checkpoint, which is important to allow time for DNA repair. Once the damage is rectified, the checkpoint must be terminated to continue the cell cycle. Two FBPs are involved deactivating Chk1 signalling: SCF(Fbxo6) and SCF(␤-TRCP1). SCF(Fbxo6) acts directly on Chk1 itself, promoting its degradation [152] . SCF(␤-TRCP1) indirectly impacts on Chk1, as it facilitates Claspin degradation, preventing ATR phosphorylation of Chk1 [153] [154] [155] . These FBPs could be envisaged to have different effects on this pathway. In terms of cancer promotion, elevated Fbxo6 would degrade Chk1 which would diminish the cell's ability to respond efficiently to DNA damage. Loss of ␤-TRCP might leave Claspin intact inappropriately and thus diminish signalling from ATM/ATR to Chk1, delaying the recovery from a damage-induced Chk1 checkpoint. The Chk1 gene itself does not appear to be recurrently mutated in cancers, suggesting alterations to its regulators may occur instead. Some evidence for this is that there is an inverse correlation between Fbxo6 levels and Chk1 in breast cancers. A third FBP mediated mechanism for regulating Chk1 might come via Fbxl16 which interacts with PP2A. Although there is no evidence for ubiquitination of PP2A by Fbxl16, it appears to negatively regulate the activity of the phosphatase [156] . Phosphorylation and activation of Chk1 by ATR is antagonized by de-phosphorylation by a number of protein phosphatases, including PP2A [157] . Thus Fbxl16 might also impact indirectly on the DNA damage responsiveness of the cell by affecting Chk1 regulators.
As mentioned above, SCF(Fbxo6) ubiquitinates Chk1, promoting its degradation after DNA damage, and this interaction is via an FBA domain in Fbxo6. This domain is thought to interact with glycosylated proteins; however, in the case of Fbxo6 and Chk1, their interaction does not appear to depend on glycosylation [152, 158] . Fbxo6 is one of several FBPs capable of recognizing glycoproteins, via an FBA domain [159] [160] [161] . This family of FBA-containing FBPs includes Fbxo2, Fbxo17, Fbxo27, and Fbxo44. They show a divergence in tissue expression, except in the brain, where they were uniformly expressed and are proposed to be involved in maintaining the quality of glycoproteins. In the case of SCF(Fbxo6), it can direct the ubiquitination and degradation of unfolded Nglycoproteins. A proteomic screen for substrates whose interaction with Fbxo6 was dependent on N-glycosylation was published, and this highlighted its role in regulating resident ER glycoproteins, ER redox, and channelling unfolded glycosylated proteins to the ERAD pathway [162] . Such an over-arching role in protein quality control is likely to play a fundamental yet redundant role in normal and disease processes, but this has yet to be fully investigated.
Another glycoprotein binding FBP, SCF(Fbxo44) impacts on HR via its ubiquitination and degradation of the breast cancer TSG, BRCA1. In a screen to identify FBPs whose abundance inversely correlated with BRCA1, SCF(Skp2)and SCF(Fbxo5) were also identified [163] . BRCA1 is a large, multi-functional protein, and also an E3 ubiquitin ligase, known to be an important regulator of HR [149] . BRCA1 interacts with a scaffold protein, BRCA2, to act as an organizing scaffold to recruit HR repair proteins. In the absence of its functions, HR is deficient. Thus, in addition to BRCA1's own regulation by auto-ubiquitination, at least three FBPs can influence its abundance. It is not known whether any PTMs, glycosylation or otherwise, direct SCF(Fbxo44) to BRCA1.
Downstream of BRCA1, Fbxo18 interacts directly with Rad51, a key protein needed for HR in mammalian cells [164] . In responding to DNA replication stress, Rad51 is recruited by the replication processivity factor, PCNA. Fbxo18 shows anti-recombinase activity by disrupting the association of Rad51 with broken DNA ends. Interestingly, a second E3 ligase, Cul4(Cdt2) has been shown to degrade Fbxo18, thus limiting its anti-recombinase activity and promoting DNA repair [165] . Cells deficient for Fbxo18 are defective in responding to DSB and therefore manage to survive replication stress but probably accumulate mutations [166, 167] . In addition to interacting with Rad51, Fbxo18 has multiple enzymatic activities. It is a DNA helicase and translocase, and can form an SCF complex to direct ubiquitination. It appears that PTMs direct the favoured enzymatic activity [168] . Fbxo18 was also the first FBP to be documented to have an alternate enzymatic activity [169] , but this is not unique [170] .
In contrast to the error-free HR pathway, non-homologous end joining (NHEJ) DSB repair is error-prone. The key regulators of this pathway are a pair of Ku proteins, Ku70 and Ku80, which form a heterodimer and are the first proteins to bind broken DNA ends [171] . There they act as a scaffold to recruit and assemble the DNA repair machinery. Ku proteins also coordinate the cellular response to damage, including checkpoints and apoptotic responses. In a screen for SCF complexes that bind to DSBs, Fbxl12 was identified, and this was dependent on Ku80 [172] . SCF(Fbxl12) was subsequently found to promote the ubiquitination and degradation of Ku80. The loss of Ku80 would have a detrimental effect on genome integrity in cells, as it is needed for NHEJ and at telomeres, where Ku80 protects them from being recognized as DSBs and thus from resection and recombination. Another E3 ligase impacting on telomeres is SCF(Fbxo4), which promotes the ubiquitination and degradation of a protein, TRF1, which is important for maintaining telomere length. This role might make Fbxo4 a factor in extending the lifespan of nascent transforming cells, as the over-expression of Fbxo4 reduces TRF1 levels, which results in gradual telomere lengthening, and conversely, the reduction in Fbxo4 expression results in telomere erosion. As such TRF1 may have a proto-oncogenic role in immortalizing cells in a similar manner to hTERT over-expression. Interestingly, TRF1 is also a substrate for SCF(␤-TRCP) [173] . Loss of these FBPs would therefore be predicted to precipitate crisis in cells.
Another major arena for damage to occur is during DNA replication, otherwise known as replication stress. An adequate and balanced pool of dNTPs is essential for this, and this is regulated by ribonucleotide reductases. It has been shown that SCF(Fbxo1) interacts with RRM2 and degrades it [174] . However, under DNA damaging conditions, Fbxo1 degradation is induced by ATR signalling, to enable RRM2 to be expressed and increase the pools of dNTPs during repair.
The cross-regulation of E3 ligases is exemplified by the discovery that SCF(Fbxo11) promotes the ubiquitination and degradation of Cdt2, the substrate-specifying subunit of a Cullin4 based ubiquitin ligase [175] that regulates both normal cell cycle progression and genome stability. Several key proteins that are ubiquitinated and degraded by the Cul4(Cdt2) E3 ligase include the replication licensing protein Cdt1, which recruits the MCM2-7 replicative helicase to pre-replication complexes, the cyclin-dependent kinase inhibitor p21, and the histone monomethyl transferase Set8 ( [176] ). Cdt1 is also a substrate for SCF(Fbxo31) ligase during G2 phase of the cell cycle causing its degradation and thus preventing re-replication of the DNA after S phase (see above) [36] . This is important for genomic integrity, as is evidenced by the fact that Fbxo31 depletion caused stabilization of Cdt1 and re-initiation of DNA synthesis.
Cell metabolism, mitochondria, and oxidative stress
A change in cell metabolism, typified by the Warburg effect, whereby cancer cells utilize glycolysis as a means to generate ATP under aerobic conditions, is well documented [177] [178] [179] . This shift from oxidative phosphorylation (OXPHOS) to glycolysis is aided by oncogenic signalling and hypoxia induced by excessive proliferation. SCF(Skp2) has been proposed to promote the ability of cells to shift to aerobic glycolysis via its ubiquitin-mediated activation and translocation of the Ser/Thr kinase Akt [180] , which stimulates glucose uptake and consumption [181] . SCF(Fbxw7) has been shown to promote ubiquitin-mediated degradation of enolase 1 (Eno1), a key glycolytic enzyme, which also impacts on cell growth and tolerance of hypoxia [182] , and SCF(␤-TRCP) ubiquitinates PFKFB3, an enzyme synthesizing fructose 2,6-bisphosphate, as does APC/C(Cdh1) [183] .
Whilst most cancer cells utilise aerobic glycolysis for ATP production, mitochondrial function is still important. Cancer cells can utilise OXPHOS to aid in metabolism under enabling conditions, and mitochondria are also important for contributing to the redox potential of the cell, regulating calcium homeostasis and apoptosis, and also for the generation of intermediates for macromolecule biosynthesis. Therefore, regulation of mitochondrial dynamics and function is central, and several FBPs play key roles in this process. For example, SCF(Fbxo15) ubiquitinates the enzyme cardiolipin synthase 1 (CLS1) promoting its proteasomal degradation [184] . CLS1 synthesizes cardiolipin, which is found on the inner mitochondrial membrane, and is essential for mitochondrial function both in a structural and physiological capacity [185] . Interestingly, Fbxo15 has been shown to interact with CLS1 after it is phosphorylated by PINK1, a mitochondrial kinase that accumulates on the mitochondrial outer membrane under stress conditions [184] . PINK1 functions in a pathway involving the E3 ubiquitin ligase Parkin, and together they regulate the autophagy removal of mitochondria (mitophagy) by mediating the phosphorylation and ubiquitination of mitochondrial proteins. Both are implicated as causative agents in Parkinson's disease (PD). Recently, PINK1 has been shown to phosphorylate ubiquitin, on Ser65, as well as the Ubl domain of Parkin, which boosts its ligase activity [186] [187] [188] [189] . Another protein that functions in this pathway to induce mitophagy under stress conditions is Fbxo7 [190] , also mutated in PD. It has its own mitochondrial targeting sequence, and can directly interact with both PINK1 and Parkin to promote mitophagy [190] .
The over-expression of another FBP, Fbxl7, damages mitochondria, producing depolarization and a reduced ATP output, and ultimately induces apoptosis. SCF(Fbxl7) was shown to interact with and induce the degradation of survivin, a protein that is important for mitochondrial bioenergetics and many other cellular functions, including stem cell maintenance, cell motility and migration, and cell division when it is a member of the chromosomal passenger complex, [191, 192] . The toxicity of Fbxl7 over-expression in cells can be bypassed by the over-expression of survivin [192] . In fact, the expression of survivin in numerous epithelial cancers is strongly associated with poor prognosis [193] , primarily as it signifies metastatic disease, although its mechanism is unknown. It would be interesting to determine if Fbxl7 is a TSG and whether this might inversely correlate with survivin expression in cancer. This may also provide a rationale to see if Fbxl7 activity might be restored or enhanced to target survivin within tumours. The 'restoration' of TSG activity in any tumour is technically challenging. However, it has also been shown that SCF(Fbxl18) can mediate the ubiquitination of Fbxl7, which promotes its degradation, and can inhibit the pro-apoptotic effect of Fbxl7 over-expression [194] . In tumours where Fbxl7 is present, one might stabilize/enhance its levels by preventing its ubiquitination by Fbxl18.
Increased levels of reactive oxygen species (ROS) are a common feature of cancer cells both as a by-product of increased metabolism and as a cause of genetic alterations. Oxidative and electrophilic stresses, such as those generated by ROS, are sensed by a family of cap'n'collar (CNC) TFs, typified by Nrf2 (reviewed in [195] ). Nrf2 levels are normally kept low in the cell because of its interaction with Cul3(Keap1), an E3 ligase that promotes its ubiquitin-mediated degradation. However, when exposed to oxidative stress, Nrf2 translocates to the nucleus where it activates a set of genes whose products encode numerous detoxifying enzymes, anti-apoptotic proteins, proteasome subunits, and drug transporters. Anti-oxidants also liberate Nrf2 from Keap1. As a redox-sensitive TF, Nrf2 is regarded as a master regulator of redox homeostasis. In this regard, Nrf2 has been characterized as a TSG, because of its important role in protecting cells from oxidative stress. However, it also has tumour promoting activity, as it gives cancer cells a survival advantage against oxidative stress, and helps render cells resistance to chemotherapeutic agents and radiation. It would seem that context and timing of Nrf2 expression during tumourigenesis might determine its role in tumour formation. Three FBPs impact on the Nrf transcriptional programme. SCF(␤-TRCP) ubiquitinates Nrf2 and its related factor, Nrf1, which is also ubiquitinated by SCF(Fbxw7) [196] [197] [198] . Recognition by FBPs is facilitated by GSK3␤ phosphorylation, and ubiquitination promoted degradation of Nrf1/2. To activate gene expression, Nrf2 forms a heterodimer, with small MAF proteins, which bind to anti-oxidant response elements or MAF recognition elements within promoters. These response elements can however, also be repressed when bound by heterodimers of MAF protein with a distantly related CNC family member, BACH1. It has been demonstrated that SCF(Fbxl17) targets BACH1 for ubiquitin-mediated degradation, lowering the threshold for activating Nrf2-regulated gene expression under normal and stressed conditions [199] .
Invasion and migration
Another hallmark of cancer cells is their ability to disregard the mechanical and environment signals that keep cells in place within a tissue, allowing them to invade the surrounding area and migrate to secondary sites to form tumours. Changes in how a cell regulates its cytoskeletal architecture are fundamental to this, and the actin cytoskeleton is particularly important [200, 201] . p27, in addition to its well-known role in regulating the cell cycle, also has cell cycleindependent functions in the cytoplasm via its interactions with RhoA, a small GTPase that is important for the formation of actin stress fibres and focal adhesions, and with stathmin, a microtubuledestabilizing protein [202, 203] . Since SCF(Skp2) destabilizes p27, another effect of over-expression of Skp2 would be to alter cell migration and increase formation of stress fibres and focal adhesions. Another negative regulator of RhoA and also its related family members Rac1 and Rac3, is SCF(Fbxl19) [204] [205] [206] . Underscoring the importance of this pathway, at least two other E3 ubiquitin ligases target RhoA for ubiquitination: Smurf1 and Cullin3(BACURD) [207, 208] . Proteins which modulate RhoA signalling are also targeted by FBPs. DLC1 is a RhoA GTPase activating protein (GAP) that is ubiquitinated by Cul4(Fbxw5), promoting its degradation. Interestingly, in lung cancer cell lines with low levels of DLC1 expression, the suppression of Fbxw5 restored DLC1 expression, with the consequential effects being reduced RhoA signalling as well as effects on cell proliferation and anchorage-independent growth [209] . SCF(Fbxo8) negatively regulates Arf6, a class III small GTPase; it ubiquitinates Arf6, but this does not result in Arf6 turnover. Arf6 is the most divergent member of the six isoforms of this family of Arf GTPases, and it has roles in tumour invasion, cell adhesion and migration (reviewed in [210] ). As Fbxo8 negatively regulates Arf6, which enhances cell invasiveness, it might be classed as a potential TSG. mRNA and protein expression appear to be absent in samples from lung, colon, liver and breast cancers, which is consistent with this notion [211] [212] [213] .
Cortactin is an actin binding protein that cross-links F-actin subunits to regulate cell migration and cell junctions, and is thought to play a role in metastasis. It is phosphorylated by multiple kinases, including Src kinase which reduces its cross-linking activity, and ERK kinases which promotes its degradation. SCF(Fbxl5), triggered by its phosphorylation by ERK, ubiquitinates cortactin, causing its degradation by the proteasome. This results in cells exhibiting decreased migration and invasive properties [214] . Thus Fbxl5 can suppress tumour cell migration via the down-regulation of cortactin.
The epithelial to mesenchymal transition (EMT) is a normal developmental program acting during embryogenesis and induced during wound healing, which is proposed to be aberrantly revived during cancer progression [215] [216] [217] . Epithelial cells, which form characteristic tight connections with their surrounding cells to produce sheets, are prevented from moving efficiently; therefore a change in phenotype to a more mesenchymal identity allows cells to become more mobile, aiding tumorigenesis. A family of EMT TFs, including Twist 1, Snail 1/2 and Zeb1/2, are thought to precipitate the programme to enable this [218] . Several FBPs ubiquitinate these TFs, including SCF(Fbxo11), which can target Snail1/2 for degradation after their phosphorylation by protein kinase D1 [219, 220] . Fbxo11 is important for maintaining an epithelial state and its levels inversely correlate with Snail proteins in cancers [219] . However, its effects may also be mediated through its negative regulation of TGF␤ signalling, which has dual roles in tumour biology [221] . Early on, TGF␤ acts as a TSG, but later on as a promoter of tumour formation [222] . Part of this late pro-tumour effect of TGF␤ is thought to be due to its ability to reduce the expression of E-cadherin, loss of which is a marker of EMT. Another example is SCF(Fbxo45) which ubiquitinates multiple TFs important for EMT, including Snail [223] . Fbxo45 is atypical in that it binds to Skp1 via its F-box motif, but recruits an alternate Ring-finger protein known as PAM/MYCBP2. In a contradictory mechanism to promoting Snail destabilisation and therefore inhibiting EMT, Fbxo45 can stabilise N-cadherin, which is upregulated during EMT [224] . N-cadherin is a necessary factor for promoting neuronal differentiation, and is also important for the structural integrity and formation of new blood vessels. Since interfering with N-cadherin would destabilize small blood vessels, and expanding tumour growth requires angiogenesis, one might imagine that tumours would depend on Fbxo45 for their continued expansion. Fbxo45's effects on N-cadherin would therefore seem to favour EMT, and would suggest that decreasing Fbxo45 levels would have a similar effect to chemotherapies like ADH1, an Ncadherin antagonist, that has had limited clinical trials. In addition to Fbxo11 and Fbxo45, three other FBPs have been reported to date to regulate Snail, including SCF(␤-TRCP) [225] , SCF(Fbxl5) [226] , and SCF(Fbxl14), which is up-regulated under hypoxic conditions [227] . In all cases, the modification of Snail by ubiquitin promotes its degradation by the proteasome. Many other signalling pathways, including NFB, WNT/␤-catenin, and Shh, act in concert with the Snail pathway, cross-talking to influence EMT, suggesting this is an important convergence point in cancer progression, heavily influenced by a ubiquitin network [228, 229] .
Another FBP that is potentially involved in this pathway is Fbxl20. Over-expression of Fbxl20 caused increased invasion and cell motility that correlated with decreased E-cadherin, and increased ␤-catenin levels, although no direct substrate was identified [230] . A potential intermediary could be Vps34 which has recently been shown to be ubiquitinated by SCF(Fbxl20) and degraded by the proteasome [231] . Vps34, a lipid kinase, is critically involved in the production of phosphatidylinositol, which regulates many aspects of the trafficking of intracellular vesicles, including those involved in receptor signalling, autophagy, and endosomes. As such, its regulation would impact on diverse processes from proteostasis to cell signalling and receptor turnover [232] . Interestingly, Fbxl20 is a p53 response gene, and its expression is enhanced upon induction of the p53 pathway by DNA damage. In addition to this transcriptional response, the recognition of Vps34 by Fbxl20 is also regulated via phosphorylation of Thr159 by cyclin B1/Cdk1, during normal mitosis and during mitotic arrest due to DNA damage [231] . Thus p53 can impact on multiple aspects of autophagy, receptor signalling and intracellular traffic via SCF(Fbxl20)-mediated ubiquitination of Vps34.
Angiogenesis
One of the key hallmarks thought to be important for sustaining a tumour and promoting its metastasis is the promotion of angiogenesis [233] . This is a physiological response to hypoxia, which a tumour, as it expands, begins to encounter. The hypoxic stress response is regulated by the well-known Von Hippel Lindau (VHL) factor/Cul2 E3 ubiquitin ligase, which ubiquitinates and degrades hypoxia-inducible factor-␣ (HIF␣). HIF␣ binds to the transcriptional co-factor p300/CBP to regulate a swathe of genes that mediate an angiogenic response. CITED2 has high affinity for p300/CBP and competes with HIF1␣ for binding, thus it can inhibit hypoxic signalling. It has recently been described that SCF(Fbxl5) can ubiquitinate and cause the degradation of CITED2, and thus its over-expression might aid tumour formation by increasing HIF1␣ transcription [234] . Another E3 ligase shown to ubiquitinate and cause the degradation of HIF1␣ under hypoxic conditions, after its phosphorylation by GSK3␤, is SCF(Fbxw7) ligase [235] . One could imagine that loss of Fbxw7 under hypoxic stress would increase angiogenesis in tumours.
The major growth factor responsible for initiating angiogenesis is vascular endothelial growth factor (VEGF), which is produced in response to HIF␣ signalling. VEGF acts in a paracrine fashion on endothelial cells, binding and activating its cognate receptor, VEGFR2, promoting proliferation, migration, destruction of extracellular matrices, and ultimately angiogenesis. Unsurprisingly this pathway is activated by cancer cells to aid tumourigensis and presents a promising avenue for therapeutic intervention, with some limited success [236] . VEGFR2 is targeted for degradation by SCF(␤-TRCP) in papillary thyroid cancer cells, with ␤-TRCP levels inversely correlated with VEGFR2 [237] . Interestingly, VEGF-A levels were also found to inversely correlate with ␤-TRCP and contains a putative ␤-TRCP binding site, suggesting it may also be a target for this FBP, and indicating that ␤-TRCP may have tumour suppressive properties in these cells.
Concluding remarks
The determinants for whether an SCF ligase ubiquitinates a target are diverse. Many FBPs recognise substrates after PTM; however, some bind unmodified substrates, and PTMs prevent substrate recognition [238] . Furthermore, additional co-factors or the sequestration of FBPs (or substrates) to specific tissues or subcellular locations, can also change substrate availability. In addition to substrate-ligase interactions, many SCF ligases can dimerize, which is thought to lead to an augmentation in ubiquitination efficiency and possibly specification of the type of ubiquitin chain linkages. In the absence of a recognizable substrate, SCF ligases can auto-ubiquitinate and down-regulate their own abundance. In some instances, regulatory relationships exist among SCF-type ligases, and with other E3 ubiquitin ligases, where they control the abundance or functional impact of the other. For example, SCF(Skp2) can ubiquitinate and induce degradation of ␤TRCP1, likewise SCF(Fbxo3) interacts with Fbxl2, SCF(Fbxl21) with Fbxl3, SCF(Fbxl18) with Fbxl7, SCF(Fbxo11) with Cdt2, Cul4(Cdt2) with Fbxo18, SCF(␤TRCP) with Fbxo5/Emi1 and Cdh1, and APC/C(Cdh1) regulates Skp2 and Fbxw5. Fbxo11 has also been reported to interact with both ␤TRCP and Skp2 [55] . These interactions highlight the interconnected nature of ubiquitin biology. A particularly far-reaching example of cross-regulation of E3 ubiquitin and ubiquitin-like ligases is the reported regulation of two of the nine Nedd4 ligases, namely Nedd4-1 and Smurf1, by SCF(Fbxo3). In fact, the levels of all Nedd4 family members were significantly decreased in the presence of Fbxo3, suggesting they were primed for degradation by SCF(Fbxo3) [96] . By virtue of its degradation of these Nedd4 ligases, Fbxo3 indirectly affects their downstream targets, which for Nedd4-1 includes the negative regulation of Notch, Akt, IGF-1R, LATS1, MDM2, VEGF-R2, Rac, TRAF3, and PTEN, and for Smurf1, JunB, Smads, BMPRs, AMSH, RhoA, and KLF2. Collectively, these would impact on virtually all hallmarks of cancer.
From our surveys above, we identified several individual FBPs that affect multiple hallmarks (Fig. 2) , e.g., Fbxo31 can directly ubiquitinate many targets mediating stress responses in cells, hitting several cancer hallmarks (DNA damage (Mdm2), proliferation (cyclin D1, Cdt1), receptor signalling (MKK6)) (Fig. 2F) . These highly networked proteins may represent the most sensible FBPs to target therapeutically, but as can be gleaned from this review, these therapies should be considered in the context of their specific cellular network. Encouragingly, several studies firmly establish the feasibility for drug discovery of small molecules inhibiting E3 ubiquitin ligases. There are several reports on the identification of small molecules that interfere with the interactions between ubiquitin ligases and their substrates, including Mdm2-p53, CRL4(CRBN)-MEIS2, yeast SCF(Cdc4)-Sic1, SCF(Met30)-Met4 and SCF(Skp2)-p27 [239] [240] [241] [242] [243] . A recent report is on the use of lenalidomide to target Cul4(CRBN)-CK1␣ [244] . The crystal structures of several FBPs in complex with substrates, including Skp2 with p27 and CKS1, ␤TRCP1 with ␤-catenin, and Fbxw7 with cyclin E, have been elucidated, and these will aid in structure-guided drug discovery in the future (reviewed in [245] ). What is clear is that in the increasing arsenal of molecular chemotherapies, those against ubiquitin ligases will certainly figure, and thus discovering the ubiquitin networks of OG or TSG SCF ligases, for specific tumour cell types, will undoubtedly be an active area for future investigation.
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